Can switching breast cancer drugs improve outcomes? new study watches real-world results.
NCT ID NCT06928818
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 100 people in Korea with advanced HER2-positive breast cancer who take a drug called T-DM1 right after another drug, T-DXd, stops working. Researchers will track how long the cancer stays controlled and how well patients respond. The goal is to learn if this drug sequence is effective in real-world practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF BREAST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hormone pills may replace surgery for some older breast cancer patients
- AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects
- New scan may personalize breast cancer therapy
- New hope for HER2+ breast cancer: Real-World study tests daily pill pyrotinib
- New hope for advanced breast cancer: TQB2930 enters phase 3 trial
- New hope for advanced cancer: experimental drug targets HER2